Sanofi-aventis, Johns Hopkins to find new therapies for asthma
FE Report | Tuesday, 22 July 2008
Sanofi-aventis has signed a three year agreement with the Division of Allergy and Clinical Immunology (ACI) of The Johns Hopkins University School of Medicine, Baltimore, Maryland in the USA recently.
Under the terms of this agreement, the partners will jointly work to discover and develop new ways of treating respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease (COPD), as well as immuno-allergic diseases.
For each research theme, Johns Hopkins ACI and sanofi-aventis will work on new target identification, assay development and compound screening. The two research organisations will also collaborate on the design of potential clinical studies and the selection of biomarkers.
"This collaboration will allow sanofi-aventis and Johns Hopkins ACI to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD", said Dr. Marc Cluzel, Senior Vice President, Research and Development, sanofi-aventis.
Under the terms of this agreement, the partners will jointly work to discover and develop new ways of treating respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease (COPD), as well as immuno-allergic diseases.
For each research theme, Johns Hopkins ACI and sanofi-aventis will work on new target identification, assay development and compound screening. The two research organisations will also collaborate on the design of potential clinical studies and the selection of biomarkers.
"This collaboration will allow sanofi-aventis and Johns Hopkins ACI to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD", said Dr. Marc Cluzel, Senior Vice President, Research and Development, sanofi-aventis.